Radius Health, Inc. (RDUS)
USD 29.11
(0.73%)
USD 29.11
(0.73%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -3.92 Million USD | -101.74% |
| 2022 | 225.9 Million USD | 5.7% |
| 2021 | 213.72 Million USD | 3018.31% |
| 2020 | 6.85 Million USD | 106.11% |
| 2019 | -112.22 Million USD | 45.0% |
| 2018 | -204.06 Million USD | 18.04% |
| 2017 | -248.97 Million USD | -34.62% |
| 2016 | -184.94 Million USD | -86.67% |
| 2015 | -99.07 Million USD | -66.82% |
| 2014 | -59.39 Million USD | 11.83% |
| 2013 | -67.36 Million USD | -4.56% |
| 2012 | -64.43 Million USD | -55.22% |
| 2011 | -41.5 Million USD | -88628.57% |
| 2010 | -46.78 Thousand USD | -46.23% |
| 2009 | -31.99 Thousand USD | 0.0% |
| 2008 | - USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 FY | -3.92 Million USD | -101.74% |
| 2023 Q1 | 8.54 Million USD | 152.37% |
| 2023 Q2 | 27.51 Million USD | 222.1% |
| 2023 Q3 | -23.67 Million USD | -186.03% |
| 2023 Q4 | -22.98 Million USD | 2.89% |
| 2022 Q4 | -16.31 Million USD | -201.46% |
| 2022 Q1 | -13.45 Million USD | -17.88% |
| 2022 Q2 | -7.87 Million USD | 41.49% |
| 2022 FY | 225.9 Million USD | 5.7% |
| 2022 Q3 | 16.07 Million USD | 304.22% |
| 2021 Q2 | -11.89 Million USD | 11.28% |
| 2021 Q3 | -17.25 Million USD | -45.14% |
| 2021 Q4 | -11.41 Million USD | 33.86% |
| 2021 Q1 | -13.4 Million USD | 5.75% |
| 2021 FY | 213.72 Million USD | 3018.31% |
| 2020 Q1 | -31.58 Million USD | -63.42% |
| 2020 Q3 | 645 Thousand USD | 101.73% |
| 2020 Q4 | -14.21 Million USD | -2304.34% |
| 2020 FY | 6.85 Million USD | 106.11% |
| 2020 Q2 | -37.26 Million USD | -18.01% |
| 2019 Q1 | -37.83 Million USD | -4.08% |
| 2019 Q2 | -30.26 Million USD | 20.01% |
| 2019 Q4 | -19.32 Million USD | 22.12% |
| 2019 Q3 | -24.81 Million USD | 18.0% |
| 2019 FY | -112.22 Million USD | 45.0% |
| 2018 Q1 | -57.61 Million USD | 13.68% |
| 2018 FY | -204.06 Million USD | 18.04% |
| 2018 Q4 | -36.34 Million USD | 19.62% |
| 2018 Q3 | -45.21 Million USD | 30.3% |
| 2018 Q2 | -64.87 Million USD | -12.6% |
| 2017 FY | -248.97 Million USD | -34.62% |
| 2017 Q4 | -66.74 Million USD | -19.82% |
| 2017 Q3 | -55.7 Million USD | 19.15% |
| 2017 Q2 | -68.89 Million USD | -19.56% |
| 2017 Q1 | -57.62 Million USD | -8.64% |
| 2016 Q4 | -53.04 Million USD | -13.6% |
| 2016 FY | -184.94 Million USD | -86.67% |
| 2016 Q1 | -41.12 Million USD | -21.64% |
| 2016 Q3 | -46.69 Million USD | -5.92% |
| 2016 Q2 | -44.08 Million USD | -7.18% |
| 2015 FY | -99.07 Million USD | -66.82% |
| 2015 Q2 | -22.27 Million USD | -36.55% |
| 2015 Q1 | -16.31 Million USD | 5.12% |
| 2015 Q3 | -26.67 Million USD | -19.73% |
| 2015 Q4 | -33.81 Million USD | -26.76% |
| 2014 Q1 | -11.85 Million USD | 13.16% |
| 2014 FY | -59.39 Million USD | 11.83% |
| 2014 Q4 | -17.19 Million USD | -3.26% |
| 2014 Q3 | -16.65 Million USD | -21.66% |
| 2014 Q2 | -13.68 Million USD | -15.45% |
| 2013 Q2 | -17.68 Million USD | 6.26% |
| 2013 Q3 | -17.16 Million USD | 2.94% |
| 2013 Q4 | -13.65 Million USD | 20.46% |
| 2013 FY | -67.36 Million USD | -4.56% |
| 2013 Q1 | -18.86 Million USD | 4.15% |
| 2012 Q4 | -19.68 Million USD | -22.32% |
| 2012 Q1 | -11.97 Million USD | -18.47% |
| 2012 Q2 | -16.67 Million USD | -39.23% |
| 2012 Q3 | -16.09 Million USD | 3.52% |
| 2012 FY | -64.43 Million USD | -55.22% |
| 2011 Q4 | -10.11 Million USD | -14.03% |
| 2011 Q1 | -10.14 Thousand USD | 59.87% |
| 2011 Q2 | -17.49 Million USD | -172413.06% |
| 2011 Q3 | -8.86 Million USD | 49.33% |
| 2011 FY | -41.5 Million USD | -88628.57% |
| 2010 Q3 | -6038.00 USD | -4.92% |
| 2010 Q2 | -5755.00 USD | 40.74% |
| 2010 FY | -46.78 Thousand USD | -46.23% |
| 2010 Q1 | -9711.00 USD | -93.72% |
| 2010 Q4 | -25.27 Thousand USD | -318.65% |
| 2009 FY | -31.99 Thousand USD | 0.0% |
| 2009 Q4 | -5013.00 USD | 20.73% |
| 2009 Q3 | -6324.00 USD | 4.51% |
| 2009 Q2 | -6623.00 USD | 52.8% |
| 2009 Q1 | -14.03 Thousand USD | 0.0% |
| 2008 Q3 | -7044.00 USD | 0.0% |
| 2008 Q4 | - USD | 100.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 97.537% |
| PainReform Ltd. | -9.58 Million USD | 59.046% |
| Alvotech | -354.86 Million USD | 98.894% |
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 102.351% |
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | 108.356% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | 74.01% |
| Journey Medical Corporation | -2.07 Million USD | -89.339% |
| Dynavax Technologies Corporation | -37.02 Million USD | 89.4% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 97.477% |
| Bright Green Corporation | -8.89 Million USD | 55.856% |
| Pacira BioSciences, Inc. | 87.67 Million USD | 104.477% |
| Embecta Corp. | 221.5 Million USD | 101.772% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | 17.978% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | 17.978% |
| SCYNEXIS, Inc. | 72.66 Million USD | 105.401% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | 71.177% |
| Silver Spike Investment Corp. | 7.34 Million USD | 153.473% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | -56.05% |
| Alpha Teknova, Inc. | -35.56 Million USD | 88.963% |
| Safety Shot Inc | -12.18 Million USD | 67.786% |
| Procaps Group, S.A. | 38.97 Million USD | 110.071% |
| Cosmos Health Inc. | -21.83 Million USD | 82.021% |
| Theratechnologies Inc. | -10.62 Million USD | 63.066% |
| Harrow Health, Inc. | 580 Thousand USD | 776.724% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | 16.507% |
| Biofrontera Inc. | -22.67 Million USD | 82.692% |
| DURECT Corporation | -36.88 Million USD | 89.359% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | 25.508% |
| Cronos Group Inc. | -81.37 Million USD | 95.177% |
| OptiNose, Inc. | -22.74 Million USD | 82.746% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 101.878% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 89.975% |
| RedHill Biopharma Ltd. | 12.63 Million USD | 131.072% |
| Organogenesis Holdings Inc. | 12.52 Million USD | 131.337% |
| Guardion Health Sciences, Inc. | -4.33 Million USD | 9.485% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | 36.804% |
| Universe Pharmaceuticals INC | -3.52 Million USD | -11.292% |
| ProPhase Labs, Inc. | -21.61 Million USD | 81.84% |
| Phibro Animal Health Corporation | 53.31 Million USD | 107.362% |
| Procaps Group S.A. | 52.32 Million USD | 107.501% |
| TherapeuticsMD, Inc. | -8.52 Million USD | 53.948% |
| Viatris Inc. | 766.2 Million USD | 100.512% |
| Rockwell Medical, Inc. | -6.67 Million USD | 41.154% |
| Aytu BioPharma, Inc. | -5.25 Million USD | 25.295% |
| SIGA Technologies, Inc. | 83.62 Million USD | 104.694% |
| Tilray Brands, Inc. | -174.74 Million USD | 97.754% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | 142.064% |
| Shineco, Inc. | -17.06 Million USD | 77.001% |
| PetIQ, Inc. | 60.01 Million USD | 106.54% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | 17.137% |
| Incannex Healthcare Limited | -30.04 Million USD | 86.935% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 101.564% |
| Alimera Sciences, Inc. | -1.47 Million USD | -166.825% |
| Assertio Holdings, Inc. | -243.53 Million USD | 98.388% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | 33.389% |
| Clever Leaves Holdings Inc. | -15.59 Million USD | 74.83% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 80.424% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 97.153% |
| Hempacco Co., Inc. | -8.81 Million USD | 55.46% |
| Talphera, Inc. | -16.88 Million USD | 76.76% |
| Alvotech | -354.86 Million USD | 98.894% |
| Eagle Pharmaceuticals, Inc. | 53.45 Million USD | 107.343% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 101.076% |
| Currenc Group, Inc. | -6.64 Million USD | 40.94% |
| Kamada Ltd. | 10.06 Million USD | 139.0% |
| Indivior PLC | -4 Million USD | 1.875% |
| Evoke Pharma, Inc. | -7.43 Million USD | 47.18% |
| Flora Growth Corp. | -50.35 Million USD | 92.205% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 80.424% |
| Evolus, Inc. | -49.23 Million USD | 92.028% |
| HUTCHMED (China) Limited | 18.37 Million USD | 121.361% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 101.993% |
| Akanda Corp. | -10.05 Million USD | 60.951% |